Drug Trial Radar · NCT07168434
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
406
Planned (sponsor's estimate)
Start
Oct 22, 2025
Primary completion
Oct 11, 2026
Study completion Oct 11, 2026
Sponsor
- Lead sponsor
- BiocodexIndustry
- Sponsor type
- Industry
- First posted
- Sep 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-blind, randomized (group assignment by chance), placebo-controlled, multicenter trial which will be conducted over a 13.5-months period The main objective of the research is to demonstrate the efficacy of Saccharomyces boulardii CNCM I-745 on global IBS symptoms, measured by the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), in comparison to placebo after 8 weeks. Secondary efficacy objectives are to evaluate the impact of Saccharomyces boulardii CNCM I-745 on quality of life of IBS patients and on global and individual IBS symptoms, using the IBS-SSS, in comparison to placebo at regular intervals over a 3-month treatment period. This research also aims to evaluate the proportion of patients who improved ≥ 50 points on IBS-SSS and the proportion of responders according to the European Medicines Agency (EMA) definition (based on the patient's global assessment of efficacy and on abdominal pain score), after 8 weeks of treatment. Secondary safety objective is to evaluate the safety profile and tolerability of Saccharomyces boulardii CNCM I-745 capsules 500 mg/day in IBS patients in comparison to placebo
Conditions
- IBS (Irritable Bowel Syndrome)
- IBS-D (Diarrhea-predominant)
- IBS, Mixed Symptoms
Interventions
Saccharomyces Boulardii 250 MGDrug
Saccharomyces boulardii CNCM I-745, 250 mg, 2 capsules/day
Placebo 250 mgDrug
Placebo, 250mg, 2 capsules/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate the efficacy of Saccharomyces boulardii CNCM I-745 on global Irritable Bowel Syndrome (IBS) symptoms, measured by the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), in comparison to placebo after 8 weeks.Time frame: From baseline to day 56
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Hospital de Braga
Braga, Portugal · Recruiting
Hospital da Luz
Lisbon, Portugal · Not yet recruiting
Hospital Universitario Vall d'Hebron
Barcelona, Spain · Not yet recruiting
Hospital Universitario de León
León, Spain · Recruiting
Hospital Universitario Gregorio Marañon & Centro de Salud Pavones
Madrid, Spain · Recruiting
Hospital Clínico San Carlos
Madrid, Spain · Not yet recruiting
Hospital Universitario La Paz & Hospital Carlos III
Madrid, Spain · Not yet recruiting
Hospital Universitario Regional de Málaga
Málaga, Spain · Not yet recruiting
Hospital Universitario Costa del Sol
Marbella, Spain · Not yet recruiting
Hospital Universitario Central de Asturias & Centro de Salud la Lila
Oviedo, Spain · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.